FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.

Katoh, M. & Nakagama, H. FGF receptors: cancer biology and therapeutics. Med. Res. Rev. 34, 280–300 (2014).

pubmed: 23696246 doi: 10.1002/med.21288

Babina, I. S. & Turner, N. C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17, 318–332 (2017).

pubmed: 28303906 doi: 10.1038/nrc.2017.8

Krook, M. A. et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br. J. Cancer 124, 880–892 (2021).

pubmed: 33268819 doi: 10.1038/s41416-020-01157-0

Hung, K. L. et al. Targeted profiling of human extrachromosomal DNA by CRISPR–CATCH. Nat. Genet. 54, 1746–1754 (2022).

pubmed: 36253572 pmcid: 9649439 doi: 10.1038/s41588-022-01190-0

Singh, D. et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231–1235 (2012).

pubmed: 22837387 pmcid: 3677224 doi: 10.1126/science.1220834

Wu, Y. M. et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636–647 (2013).

pubmed: 23558953 pmcid: 3694764 doi: 10.1158/2159-8290.CD-13-0050

Reeser, J. W. et al. Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors. J. Mol. Diagn. 19, 682–696 (2017).

pubmed: 28802831 pmcid: 5975628 doi: 10.1016/j.jmoldx.2017.05.006

Jain, P. et al. Novel FGFR2-INA fusion identified in two low-grade mixed neuronal-glial tumors drives oncogenesis via MAPK and PI3K/mTOR pathway activation. Acta Neuropathol. 136, 167–169 (2018).

pubmed: 29767381 pmcid: 6015095 doi: 10.1007/s00401-018-1864-5

Qin, A. et al. Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling. J. Thorac. Oncol. 14, 54–62 (2019).

pubmed: 30267839 doi: 10.1016/j.jtho.2018.09.014

Liu, Y. J. et al. Calcified chondroid mesenchymal neoplasms with FN1-receptor tyrosine kinase gene fusions including FGFR2, FGFR1, MERTK, NTRK1, and TEK: a molecular and clinicopathologic analysis. Mod. Pathol. 34, 1373–1383 (2021).

pubmed: 33727696 doi: 10.1038/s41379-021-00786-x

Gu, W. et al. Comprehensive identification of FGFR1-4 alterations in 5557 Chinese patients with solid tumors by next-generation sequencing. Am. J. Cancer Res. 11, 3893–3906 (2021).

pubmed: 34522456 pmcid: 8414391

Tao, Z. et al. Profiling receptor tyrosine kinase fusions in chinese breast cancers. Front. Oncol. 11, 741142 (2021).

pubmed: 34650924 pmcid: 8506003 doi: 10.3389/fonc.2021.741142

Georgantzoglou, N., Shen, G., Jour, G. & Linos, K. A case of FN1-fused calcified chondroid mesenchymal neoplasm of the hand with novel FGFR3 partner gene. Genes Chromosomes Cancer 62, 237–241 (2023).

pubmed: 36504176 doi: 10.1002/gcc.23115

Katoh, M. & Katoh, M. Precision medicine for human cancers with Notch signaling dysregulation. Int. J. Mol. Med. 45, 279–297 (2020).

pubmed: 31894255

Helsten, T. et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer Res. 22, 259–267 (2016).

pubmed: 26373574 doi: 10.1158/1078-0432.CCR-14-3212

Sun, Y. et al. A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients. Ann. Transl. Med. 8, 1290 (2020).

pubmed: 33209870 pmcid: 7661893 doi: 10.21037/atm-20-5118

Katoh, M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat. Rev. Clin. Oncol. 16, 105–122 (2019).

pubmed: 30367139 doi: 10.1038/s41571-018-0115-y

Katoh, M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis. Int. J. Mol. Med. 38, 3–15 (2016).

pubmed: 27245147 pmcid: 4899036 doi: 10.3892/ijmm.2016.2620

Porta, C., Giglione, P., Liguigli, W. & Paglino, C. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Future Oncol. 11, 39–50 (2015).

pubmed: 25572783 doi: 10.2217/fon.14.208

Hilberg, F. et al. Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases. J. Pharmacol. Exp. Ther. 364, 494–503 (2018).

pubmed: 29263244 pmcid: 6040086 doi: 10.1124/jpet.117.244129

Loriot, Y. et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 381, 338–348 (2019).

pubmed: 31340094 doi: 10.1056/NEJMoa1817323

Goyal, L. et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N. Engl. J. Med. 388, 228–239 (2023).

pubmed: 36652354 doi: 10.1056/NEJMoa2206834

Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671–684 (2020).

pubmed: 32203698 pmcid: 8461541 doi: 10.1016/S1470-2045(20)30109-1

Javle, M. et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol. Hepatol. 6, 803–815 (2021).

pubmed: 34358484 doi: 10.1016/S2468-1253(21)00196-5

Gotlib, J. et al. A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement. Blood 138, 385 (2021).

doi: 10.1182/blood-2021-148103

Katoh, M. WNT and FGF gene clusters. Int. J. Oncol. 21, 1269–1273 (2002).

pubmed: 12429977

Ornitz, D. M. & Itoh, N. The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4, 215–266 (2015).

pubmed: 25772309 pmcid: 4393358 doi: 10.1002/wdev.176

Li, X. The FGF metabolic axis. Front. Med. 13, 511–530 (2019).

pubmed: 31495905 pmcid: 7102389 doi: 10.1007/s11684-019-0711-y

Eswarakumar, V. P., Lax, I. & Schlessinger, J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor. Rev. 16, 139–149 (2005).

pubmed: 15863030 doi: 10.1016/j.cytogfr.2005.01.001

Katoh, M. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol. Sci. 37, 1081–1096 (2016).

pubmed: 27992319 doi: 10.1016/j.tips.2016.10.003

Chen, L. et al. Structural basis for FGF hormone signalling. Nature 618, 862–870 (2023).

pubmed: 37286607 pmcid: 10284700 doi: 10.1038/s41586-023-06155-9

Chen, H. et al. Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases. eLife 6, e21137 (2017).

pubmed: 28166054 pmcid: 5293489 doi: 10.7554/eLife.21137

Marsiglia, W. M. et al. A conserved allosteric pathway in tyrosine kinase regulation. Structure 27, 1308–1315 (2019).

pubmed: 31204250 pmcid: 6687525 doi: 10.1016/j.str.2019.05.002

Chioni, A. M. & Grose, R. P. Biological significance and targeting of the FGFR axis in cancer. Cancers 13, 5681 (2021).

pubmed: 34830836 pmcid: 8616401 doi: 10.3390/cancers13225681

Wong, A., Lamothe, B., Lee, A., Schlessinger, J. & Lax, I. FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc. Natl Acad. Sci. USA 99, 6684–6689 (2002).

pubmed: 11997436 pmcid: 124463 doi: 10.1073/pnas.052138899

Haugsten, E. M., Malecki, J., Bjørklund, S. M., Olsnes, S. & Wesche, J. Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis. Mol. Biol. Cell 19, 3390–3403 (2008).

pubmed: 18480409 pmcid: 2488279 doi: 10.1091/mbc.e07-12-1219

Guo, C. et al. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia. Cell Signal. 20, 1471–1477 (2008).

pubmed: 18485666 pmcid: 2675614 doi: 10.1016/j.cellsig.2008.04.001

Porębska, N. et al. Targeting cellular trafficking of fibroblast growth factor receptors as a strategy for selective cancer treatment. J. Clin. Med. 8, 7 (2018).

pubmed: 30577533 pmcid: 6352210 doi: 10.3390/jcm8010007

Cullen, P. J. & Steinberg, F. To degrade or not to degrade: mechanisms and significance of endocytic recycling. Nat. Rev. Mol. Cell Biol. 19, 679–696 (2018).

pubmed: 30194414 doi: 10.1038/s41580-018-0053-7

Dai, S., Zhou, Z., Chen, Z., Xu, G. & Chen, Y. Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors. Cells 8, 614 (2019).

pubmed: 31216761 pmcid: 6627960 doi: 10.3390/cells8060614

Rouanne, M. et al. Novel therapeutic targets in advanced urothelial carcinoma. Crit. Rev. Oncol. Hematol. 98, 106–115 (2016).

pubmed: 26589398 doi: 10.1016/j.critrevonc.2015.10.021

Bahleda, R. et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin. Cancer Res. 25, 4888–4897 (2019).

pubmed: 31088831 doi: 10.1158/1078-0432.CCR-18-3334

Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 70, 404–423 (2020).

pubmed: 32767764 doi: 10.3322/caac.21631

Ardizzone, A. et al. Role of fibroblast growth factors receptors (FGFRs) in brain tumors, focus on astrocytoma and glioblastoma. Cancers 12, 3825 (2020).

pubmed: 33352931 pmcid: 7766440 doi: 10.3390/cancers12123825

Georgescu, M. M., Islam, M. Z., Li, Y., Traylor, J. & Nanda, A. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs. Acta Neuropathol. Commun. 9, 69 (2021).

pubmed: 33853673 pmcid: 8048363 doi: 10.1186/s40478-021-01170-1

Schittenhelm, J. et al. FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma. Neurooncol. Pract. 8, 209–221 (2021).

pubmed: 33898054

Sobhani, N., Fan, C., Flores-Villanueva, P. O., Generali, D. & Li, Y. The fibroblast growth factor receptors in breast cancer: from oncogenesis to better treatments. Int. J. Mol. Sci. 21, 2011 (2020).

pmcid: 7139621 doi: 10.3390/ijms21062011

Santolla, M. F. & Maggiolini, M. The FGF/FGFR system in breast cancer: oncogenic features and therapeutic perspectives. Cancers 12, 3029 (2020).

pubmed: 33081025 pmcid: 7603197 doi: 10.3390/cancers12103029

Francavilla, C. & O’Brien, C. S. Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer. Open Biol. 12, 210373 (2022).

pubmed: 35193394 pmcid: 8864352 doi: 10.1098/rsob.210373

Mahipal, A., Tella, S. H., Kommalapati, A., Anaya, D. & Kim, R. FGFR2 genomic aberrations: achilles heel in the management of advanced cholangiocarcinoma. Cancer Treat. Rev. 78, 1–7 (2019).

pubmed: 31255945 doi: 10.1016/j.ctrv.2019.06.003

Vogel, A., Segatto, O., Stenzinger, A. & Saborowski, A. FGFR2 inhibition in cholangiocarcinoma. Annu. Rev. Med. 74, 293–306 (2023).

pubmed: 36170665 doi: 10.1146/annurev-med-042921-024707

Ilyas, S. I. et al. Cholangiocarcinoma — novel biological insights and therapeutic strategies. Nat. Rev. Clin. Oncol. 20, 470–486 (2023).

pubmed: 37188899 pmcid: 10601496 doi: 10.1038/s41571-023-00770-1

Pearson, A. et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 6, 838–851 (2016).

pubmed: 27179038 pmcid: 5338732 doi: 10.1158/2159-8290.CD-15-1246

Jogo, T. et al. Circulating tumor DNA analysis detects FGFR2 amplification and concurrent genomic alterations associated with FGFR inhibitor efficacy in advanced gastric cancer. Clin. Cancer Res. 27, 5619–5627 (2021).

pubmed: 34376535 pmcid: 9401460 doi: 10.1158/1078-0432.CCR-21-1414

Zingg, D. et al. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 608, 609–617 (2022).

pubmed: 35948633 pmcid: 9436779 doi: 10.1038/s41586-022-05066-5

Wang, H. et al. Advances of fibroblast growth factor/receptor signaling pathway in hepatocellular carcinoma and its pharmacotherapeutic targets. Front. Pharmacol. 12, 650388 (2021).

pubmed: 33935756 pmcid: 8082422 doi: 10.3389/fphar.2021.650388

Gadaleta, R. M. & Moschetta, A. Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver. J. Hepatol. 75, 1440–1451 (2021).

pubmed: 34364916 doi: 10.1016/j.jhep.2021.07.029

Tao, Z., Cui, Y., Xu, X. & Han, T. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 119, e2208844119 (2022).

pubmed: 36179047 pmcid: 9546626 doi: 10.1073/pnas.2208844119

Weiss, J. et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2, 62ra93 (2010).

pubmed: 21160078 pmcid: 3990281 doi: 10.1126/scitranslmed.3001451

Zhou, Z. et al. Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases. Cancer Biol. Med. 18, 490–501 (2021).

pubmed: 33710807 pmcid: 8185861 doi: 10.20892/j.issn.2095-3941.2020.0120

Pacini, L., Jenks, A. D., Lima, N. C. & Huang, P. H. Targeting the fibroblast growth factor receptor (FGFR) family in lung cancer. Cells 10, 1154 (2021).

pubmed: 34068816 pmcid: 8151052 doi: 10.3390/cells10051154

Pollock, P. M. et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26, 7158–7162 (2007).

pubmed: 17525745 pmcid: 2871595 doi: 10.1038/sj.onc.1210529

Guo, F., Zhang, H., Jia, Z., Cui, M. & Tian, J. Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer. Am. J. Cancer Res. 8, 1317–1331 (2018).

pubmed: 30094104 pmcid: 6079151

Zhu, D. L., Tuo, X. M., Rong, Y., Zhang, K. & Guo, Y. Fibroblast growth factor receptor signaling as therapeutic targets in female reproductive system cancers. J. Cancer 11, 7264–7275 (2020).

pubmed: 33193890 pmcid: 7646179 doi: 10.7150/jca.44727

André, F. & Cortés, J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res. Treat. 150, 1–8 (2015).

pubmed: 25677745 pmcid: 4344551 doi: 10.1007/s10549-015-3301-y

Papadopoulos, K. P. et al. A phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br. J. Cancer 117, 1592–1599 (2017).

pubmed: 28972963 pmcid: 5729432 doi: 10.1038/bjc.2017.330

Perera, T. P. S. et al. Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol. Cancer Ther. 16, 1010–1020 (2017).

pubmed: 28341788 doi: 10.1158/1535-7163.MCT-16-0589

Meric-Bernstam, F. et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase i dose-expansion study. Cancer Discov. 12, 402–415 (2022).

pubmed: 34551969 doi: 10.1158/2159-8290.CD-21-0697

Grünewald, S. et al. Rogaratinib: a potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int. J. Cancer 145, 1346–1357 (2019).

pubmed: 30807645 pmcid: 6766871 doi: 10.1002/ijc.32224

Tyhonas, J. S. et al. Discovery of KIN-3248, an irreversible, next generation FGFR inhibitor for the treatment of advanced tumors harboring FGFR2 and/or FGFR3 gene alterations. J. Med. Chem. 3, 1734–1746 (2024).

doi: 10.1021/acs.jmedchem.3c01819

Liu, P. C. C. et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS ONE 15, e0231877 (2020).

pubmed: 32315352 pmcid: 7313537 doi: 10.1371/journal.pone.0231877

Guagnano, V. et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2, 1118–1133 (2012).

pubmed: 23002168 doi: 10.1158/2159-8290.CD-12-0210

Gavine, P. R. et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045–2056 (2012).

pubmed: 22369928 doi: 10.1158/0008-5472.CAN-11-3034

Nakanishi, Y. et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol. Cancer Ther. 13, 2547–2558 (2014).

pubmed: 25169980 doi: 10.1158/1535-7163.MCT-14-0248

Nguyen, M. H. et al. Discovery of orally bioavailable FGFR2/FGFR3 dual inhibitors via structure-guided scaffold repurposing approach. ACS Med. Chem. Lett. 14, 312–318 (2023).

pubmed: 36923909 doi: 10.1021/acsmedchemlett.3c00003

Subbiah, V. et al. RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer Discov. 13, 2012–2031 (2023).

pubmed: 37270847 pmcid: 10481131 doi: 10.1158/2159-8290.CD-23-0475

Ballard, J. A. et al. Preclinical characterization of LOXO-435 (LOX-24350), a potent and highly isoform-selective FGFR3 inhibitor. Mol. Cancer Ther. 20, P141 (2021).

doi: 10.1158/1535-7163.TARG-21-P141

Weiss, A. et al. FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer. Mol. Cancer Ther. 18, 2194–2206 (2019).

pubmed: 31409633 doi: 10.1158/1535-7163.MCT-18-1291

Hatlen, M. A. et al. Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma. Cancer Discov. 9, 1686–1695 (2019).

pubmed: 31575540 doi: 10.1158/2159-8290.CD-19-0367

Tan, L. et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc. Natl Acad. Sci. USA 111, E4869–E4877 (2014).

pubmed: 25349422 pmcid: 4234547 doi: 10.1073/pnas.1403438111

FDA. Approval of erdafitinib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf (2019).

FDA. Approval of eutibatinib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf (2022).

FDA. Approval of infigratinib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf (2021).

FDA. Approval of pemigatinib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf (2022).

Siefker-Radtke, A. O. et al. Management of fibroblast growth factor inhibitor treatment-emergent adverse events of interest in patients with locally advanced or metastatic urothelial carcinoma. Eur. Urol. Open. Sci. 50, 1–9 (2023).

pubmed: 37101768 pmcid: 10123440 doi: 10.1016/j.euros.2022.12.019

FDA. FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma (2024).

National Comprehensive Cancer Network. NCCN Guidelines. Bladder cancer, version 3.2023, https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (2023).

NICE. Inspection of erdafitinib. https://www.nice.org.uk/guidance/indevelopment/gid-ta10937 (2023).

Pant, S. et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 24, 925–935 (2023).

pubmed: 37541273 doi: 10.1016/S1470-2045(23)00275-9

Goyal, L. et al. Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. Cancer Res. 81, CT010 (2021).

doi: 10.1158/1538-7445.AM2021-CT010

Alekseev, O., Ojuok, E. & Cousins, S. Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma. Int. J. Retin. Vitreous 7, 34 (2021).

doi: 10.1186/s40942-021-00305-9

Oladipupo, S. S. et al. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc. Natl Acad. Sci. USA 111, 13379–13384 (2014).

pubmed: 25139991 pmcid: 4169958 doi: 10.1073/pnas.1324235111

National Comprehensive Cancer Network. NCCN Guidelines. Biliary tract cancers, version 2.2023, https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf (2023).

European Medicines Agency. Pemazyre (Pemigatinib). 12/09/2023, https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre (2023).

European Medicines Agency. Lytgobi (Futibatinib). 18/07/2023, https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi (2023).

National Comprehensive Cancer Network. NCCN Guidelines. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, https://www.nccn.org/professionals/physician_gls/pdf/mlne.pdf (2023).

Loriot, Y. et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 389, 1961–1971 (2023).

pubmed: 37870920 doi: 10.1056/NEJMoa2308849

Janssen. Press release for erdafitinib. investor.jnj.com, https://www.investor.jnj.com/files/doc_news/2023/09/BALVERSA-Filing-Press-Release_FINAL.pdf (2023).

Catenacci, D. V. T. et al. Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. J. Clin. Oncol. 38, 2418–2426 (2020).

pubmed: 32167861 pmcid: 7367551 doi: 10.1200/JCO.19.01834

Wainberg, Z. A. et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 23, 1430–1440 (2022).

pubmed: 36244398 doi: 10.1016/S1470-2045(22)00603-9

Wainberg, Z. A. et al. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer, https://doi.org/10.1007/s10120-024-01466-w (2024).

Schuler, M. et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 20, 1454–1466 (2019).

pubmed: 31405822 doi: 10.1016/S1470-2045(19)30412-7

Voss, M. H. et al. A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations. Clin. Cancer Res. 25, 2699–2707 (2019).

pubmed: 30745300 pmcid: 9014845 doi: 10.1158/1078-0432.CCR-18-1959

Kommalapati, A. et al. FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice. Cancers 13, 2968 (2021).

pubmed: 34199304 pmcid: 8231807 doi: 10.3390/cancers13122968

Xie, Y. et al. FGF/FGFR signaling in health and disease. Signal Transduct. Target. Ther. 5, 181 (2020).

pubmed: 32879300 pmcid: 7468161 doi: 10.1038/s41392-020-00222-7

Han, X. et al. Conditional deletion of Fgfr1 in the proximal and distal tubule identifies distinct roles in phosphate and calcium transport. PLoS ONE 11, e0147845 (2016).

pubmed: 26839958 pmcid: 4739706 doi: 10.1371/journal.pone.0147845

Kim, R. D. et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 9, 1696–1707 (2019).

pubmed: 31575541 doi: 10.1158/2159-8290.CD-19-0555

Chan, S. L. et al. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J. Exp. Clin. Cancer Res. 41, 189 (2022).

pubmed: 35655320 pmcid: 9161616 doi: 10.1186/s13046-022-02383-5

Cowell, J. K. et al. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas. Int. J. Cancer 141, 1822–1829 (2017).

pubmed: 28646488 pmcid: 5850950 doi: 10.1002/ijc.30848

Pal, S. K. et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 8, 812–821 (2018).

pubmed: 29848605 pmcid: 6716598 doi: 10.1158/2159-8290.CD-18-0229

Goyal, L. et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 9, 1064–1079 (2019).

pubmed: 31109923 pmcid: 6677584 doi: 10.1158/2159-8290.CD-19-0182

Varghese, A. M. et al. Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. JCO Precis. Oncol. 5, 44–50 (2021).

doi: 10.1200/PO.20.00178

Silverman, I. M. et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 11, 326–339 (2021).

pubmed: 33218975 doi: 10.1158/2159-8290.CD-20-0766

Jiang, K. et al. GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo. Cancer Med. 10, 4874–4884 (2021).

pubmed: 34114373 pmcid: 8290231 doi: 10.1002/cam4.4041

Valery, M. et al. Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments. Cancers 15, 4446 (2023).

pubmed: 37760415 pmcid: 10526255 doi: 10.3390/cancers15184446

Facchinetti, F. et al. Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer. Cancer Discov. 13, 1998–2011 (2023).

pubmed: 37377403 pmcid: 10481128 doi: 10.1158/2159-8290.CD-22-1441

Guercio, B. J. et al. Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clin. Cancer Res. 29, 4586–4595 (2023).

pubmed: 37682528 doi: 10.1158/1078-0432.CCR-23-1283

Wu, Q. et al. Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma. Clin. Cancer Res. 30, 198–208 (2024).

pubmed: 37843855 doi: 10.1158/1078-0432.CCR-23-1317

Mohammadi, M., Schlessinger, J. & Hubbard, S. R. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 86, 577–587 (1996).

pubmed: 8752212 doi: 10.1016/S0092-8674(00)80131-2

Rizzo, A., Ricci, A. D. & Brandi, G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin. Investig. Drugs 30, 317–324 (2021).

pubmed: 33054456 doi: 10.1080/13543784.2021.1837774

Murugesan, K. et al. Pan-tumor landscape of fibroblast growth factor receptor 1–4 genomic alterations. ESMO Open 7, 100641 (2022).

pubmed: 36462464 pmcid: 9832751 doi: 10.1016/j.esmoop.2022.100641

Schram, A. M. et al. Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: the ReFocus study. Mol. Cancer Ther. 22, IA006 (2023).

doi: 10.1158/1535-7163.TARG-23-IA006

Iyer, G. et al. A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress). Cancer Res. 83, CT119 (2023).

doi: 10.1158/1538-7445.AM2023-CT119

Herrera-Abreu, M. T. et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 3, 1058–1071 (2013).

pubmed: 23744832 pmcid: 3770512 doi: 10.1158/2159-8290.CD-12-0569

Wu, Q. et al. EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 12, 1378–1395 (2022).

pubmed: 35420673 pmcid: 9064956 doi: 10.1158/2159-8290.CD-21-1168

Siefker-Radtke, A. O. et al. Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy. Ann. Oncol. 31, S584 (2020).

Cleary, J. M. et al. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov. 11, 2488–2505 (2021).

pubmed: 33926920 pmcid: 8690974 doi: 10.1158/2159-8290.CD-20-1669

Malchers, F. et al. Mechanisms of primary drug resistance in FGFR1-amplified lung cancer. Clin. Cancer Res. 23, 5527–5536 (2017).

pubmed: 28630215 doi: 10.1158/1078-0432.CCR-17-0478

Sansregret, L., Vanhaesebroeck, B. & Swanton, C. Determinants and clinical implications of chromosomal instability in cancer. Nat. Rev. Clin. Oncol. 15, 139–150 (2018).

pubmed: 29297505 doi: 10.1038/nrclinonc.2017.198

Donehower, L. A. et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 28, 1370–1384 (2019).

pubmed: 31365877 pmcid: 7546539 doi: 10.1016/j.celrep.2019.07.001

Baslan, T. et al. Ordered and deterministic cancer genome evolution after p53 loss. Nature 608, 795–802 (2022).

pubmed: 35978189 pmcid: 9402436 doi: 10.1038/s41586-022-05082-5

Wang, X. Y. et al. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. Theranostics 12, 260–276 (2022).

pubmed: 34987644 pmcid: 8690927 doi: 10.7150/thno.63417

Tavolari, S. & Brandi, G. Mutational landscape of cholangiocarcinoma according to different etiologies: a review. Cells 12, 1216 (2023).

pubmed: 37174616 pmcid: 10177226 doi: 10.3390/cells12091216

Subbiah, V. et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann. Oncol. 33, 522–533 (2022).

pubmed: 35176457 doi: 10.1016/j.annonc.2022.02.001

Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420–433 (2020).

pubmed: 31563503 doi: 10.1016/j.eururo.2019.09.006

Mata, D. A. et al. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3–TACC3 fusions. Acta Neuropathol. Commun. 8, 186 (2020).

pubmed: 33168106 pmcid: 7653727 doi: 10.1186/s40478-020-01058-6

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).

doi: 10.1038/nature13480

Chirnomas, D., Hornberger, K. R. & Crews, C. M. Protein degraders enter the clinic — a new approach to cancer therapy. Nat. Rev. Clin. Oncol. 20, 265–278 (2023).

pubmed: 36781982 doi: 10.1038/s41571-023-00736-3

He, M. et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct. Target. Ther. 7, 181 (2022).

pubmed: 35680848 pmcid: 9178337 doi: 10.1038/s41392-022-00999-9

Ma, L. et al. Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer. J. Med. Chem. 66, 7438–7453 (2023).

pubmed: 37220310 doi: 10.1021/acs.jmedchem.3c00150

Du, G. et al. Discovery of a potent degrader for fibroblast growth factor receptor 1/2. Angew. Chem. Int. Ed. Engl. 60, 15905–15911 (2021).

pubmed: 33915015 pmcid: 8324087 doi: 10.1002/anie.202101328

Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021).

pubmed: 33483715 pmcid: 8353572 doi: 10.1038/s41568-020-00323-z

Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 20 (2023).

pubmed: 36717905 pmcid: 9885707 doi: 10.1186/s12943-023-01723-z

Sullivan, P. M. et al. FGFR4-targeted chimeric antigen receptors combined with anti-myeloid polypharmacy effectively treat orthotopic rhabdomyosarcoma. Mol. Cancer Ther. 21, 1608–1621 (2022).

pubmed: 35877472 pmcid: 9538595 doi: 10.1158/1535-7163.MCT-22-0059

Tian, M. et al. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell Rep. Med. 4, 101212 (2023).

pubmed: 37774704 pmcid: 10591056 doi: 10.1016/j.xcrm.2023.101212

Sun, H. D. et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am. J. Physiol. Endocrinol. Metab. 292, E964–E976 (2007).

pubmed: 17132826 doi: 10.1152/ajpendo.00089.2006

Sommer, A. et al. Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors. Cancer Res. 76, 6331–6339 (2016).

pubmed: 27543601 doi: 10.1158/0008-5472.CAN-16-0180

Kamath, A. V. et al. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma. Cancer Chemother. Pharmacol. 69, 1071–1078 (2012).

pubmed: 22203368 doi: 10.1007/s00280-011-1807-5

Bartz, R. et al. Preclinical development of U3-1784, a novel FGFR4 antibody against cancer, and avoidance of its on-target toxicity. Mol. Cancer Ther. 18, 1832–1843 (2019).

pubmed: 31350344 doi: 10.1158/1535-7163.MCT-18-0048

Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327–344 (2021).

pubmed: 33558752 pmcid: 8287784 doi: 10.1038/s41571-021-00470-8

Fu, Z. et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther. 7, 93 (2022).

pubmed: 35318309 pmcid: 8941077 doi: 10.1038/s41392-022-00947-7

Kollmannsberger, C. et al. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer. Invest. New Drugs 39, 1613–1623 (2021).

pubmed: 34264412 doi: 10.1007/s10637-021-01146-x

Kim, S. B. et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer. Target. Oncol. 14, 591–601 (2019).

pubmed: 31502117 pmcid: 6797631 doi: 10.1007/s11523-019-00670-4

Wickstroem, K. et al. Preclinical combination studies of an FGFR2 targeted thorium-227 conjugate and the ATR inhibitor BAY 1895344. Int. J. Radiat. Oncol. Biol. Phys. 105, 410–422 (2019).

pubmed: 31255687 doi: 10.1016/j.ijrobp.2019.06.2508

Nasr, D. et al. Radioimmunoconjugates in the age of modern immuno-oncology. Life Sci. 310, 121126 (2022).

pubmed: 36309222 doi: 10.1016/j.lfs.2022.121126

Harding, T. C. et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med. 5, 178ra39 (2013).

pubmed: 23536011 doi: 10.1126/scitranslmed.3005414

Tolcher, A. W. et al. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann. Oncol. 27, 526–532 (2016).

pubmed: 26646757 doi: 10.1093/annonc/mdv591

Morgensztern, D. et al. An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer 136, 74–79 (2019).

pubmed: 31446228 doi: 10.1016/j.lungcan.2019.08.011

van Brummelen, E. M. J. et al. A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Invest. New Drugs 38, 457–467 (2020).

pubmed: 31065954 doi: 10.1007/s10637-019-00783-7

Gonçalves, D. et al. In vitro and in vivo characterization of recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS ONE 15, e0244368 (2020).

pubmed: 33370388 pmcid: 7769458 doi: 10.1371/journal.pone.0244368

Ishiwata, T. Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells. Front. Biosci. 23, 626–639 (2018).

doi: 10.2741/4609

Epstein, R. J., Tian, L. J. & Gu, Y. F. 2b or not 2b: how opposing FGF receptor splice variants are blocking progress in precision oncology. J. Oncol. 2021, 9955456 (2021).

pubmed: 34007277 pmcid: 8110382 doi: 10.1155/2021/9955456

Taylor, J. G. VI et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 119, 3395–3407 (2009).

pubmed: 19809159

Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).

pubmed: 34161051 pmcid: 8446332 doi: 10.1056/NEJMoa2107322

Yao, J. et al. Synthesis and evaluation of novel 99mTc-labeled FGFR2-targeting peptides. Mol. Pharm. 21, 895–903 (2024).

pubmed: 38170629 doi: 10.1021/acs.molpharmaceut.3c00998

Lin, C. C. et al. Receptor tyrosine kinases regulate signal transduction through a liquid-liquid phase separated state. Mol. Cell 82, 1089–1106 (2022).

pubmed: 35231400 pmcid: 8937303 doi: 10.1016/j.molcel.2022.02.005

Hart, K. C., Robertson, S. C. & Donoghue, D. J. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol. Biol. Cell 12, 931–942 (2001).

pubmed: 11294897 pmcid: 32277 doi: 10.1091/mbc.12.4.931

Szybowska, P., Kostas, M., Wesche, J., Wiedlocha, A. & Haugsten, E. M. Cancer mutations in FGFR2 prevent a negative feedback loop mediated by the ERK1/2 pathway. Cells 8, 518 (2019).

pubmed: 31146385 pmcid: 6627556 doi: 10.3390/cells8060518

Turner, N. et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085–2094 (2010).

pubmed: 20179196 pmcid: 2832818 doi: 10.1158/0008-5472.CAN-09-3746

Razavi, P. et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34, 427–438 (2018).

pubmed: 30205045 pmcid: 6327853 doi: 10.1016/j.ccell.2018.08.008

Sircoulomb, F. et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol. Med. 3, 153–166 (2011).

pubmed: 21328542 pmcid: 3395112 doi: 10.1002/emmm.201100121

Rutkovsky, A. C. et al. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer. BMC Cancer 19, 491 (2019).

pubmed: 31122207 pmcid: 6533768 doi: 10.1186/s12885-019-5667-4

Yuan, G. et al. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature 590, 504–508 (2021).

pubmed: 33536620 pmcid: 7895461 doi: 10.1038/s41586-020-03170-y

Condorelli, R. et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 30, 365–373 (2019).

pubmed: 30715161 doi: 10.1093/annonc/mdz036

Yao, Q. et al. Epigenetic alterations in keratinocyte carcinoma. J. Invest. Dermatol. 141, 1207–1218 (2021).

pubmed: 33212152 doi: 10.1016/j.jid.2020.10.018

DeSalvo, J. et al. ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control. J. Clin. Invest. 131, e141908 (2021).

pubmed: 33983905 pmcid: 8245179 doi: 10.1172/JCI141908

Lötsch, D. et al. Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Acta Neuropathol. 142, 339–360 (2021).

pubmed: 34046693 pmcid: 8270873 doi: 10.1007/s00401-021-02327-x

Mouron, S. et al. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. Breast Cancer Res. 23, 21 (2021).

pubmed: 33579347 pmcid: 7881584 doi: 10.1186/s13058-021-01398-8

Formisano, L. et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER

pubmed: 30914635 pmcid: 6435685 doi: 10.1038/s41467-019-09068-2

Coombes, R. C. et al. Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat. Commun. 13, 3246 (2022).

pubmed: 35688802 pmcid: 9187670 doi: 10.1038/s41467-022-30666-0

Mayer, I. A. et al. A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ ER+/ HER2- negative metastatic breast cancer (MBC). Cancer Res. 81, PD1–PD03 (2021).

doi: 10.1158/1538-7445.SABCS20-PD1-03

Giacomini, A. et al. The FGF/FGFR system in the physiopathology of the prostate gland. Physiol. Rev. 101, 569–610 (2021).

pubmed: 32730114 doi: 10.1152/physrev.00005.2020

Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474–489 (2017).

pubmed: 29017058 pmcid: 5750052 doi: 10.1016/j.ccell.2017.09.003

Cheng, C. et al. Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer. Nat. Cancer 3, 565–580 (2022).

pubmed: 35624341 doi: 10.1038/s43018-022-00380-3

Chan, J. M. et al. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 377, 1180–1191 (2022).

pubmed: 35981096 pmcid: 9653178 doi: 10.1126/science.abn0478

Chiodelli, P. et al. FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer. Cancer Lett. 526, 217–224 (2022).

pubmed: 34861311 doi: 10.1016/j.canlet.2021.11.030

Kraehenbuehl, L., Weng, C. H., Eghbali, S., Wolchok, J. D. & Merghoub, T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37–50 (2022).

pubmed: 34580473 doi: 10.1038/s41571-021-00552-7

Cristescu, R. et al. Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types. Clin. Cancer Res. 28, 1680–1689 (2022).

pubmed: 34965943 doi: 10.1158/1078-0432.CCR-21-3329

Petroni, G., Buqué, A., Coussens, L. M. & Galluzzi, L. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat. Rev. Drug. Discov. 21, 440–462 (2022).

pubmed: 35292771 doi: 10.1038/s41573-022-00415-5

Jing, W. et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 82, 114–129 (2022).

pubmed: 34753771 doi: 10.1158/0008-5472.CAN-21-2362

Ouyang, Y. et al. FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation. Cancer Res. 83, 4030–4046 (2023).

pubmed: 37768887 pmcid: 10722136 doi: 10.1158/0008-5472.CAN-23-1065

Katoh, M. & Katoh, M. WNT signaling and cancer stemness. Essays Biochem. 66, 319–331 (2022).

pubmed: 35837811 pmcid: 9484141 doi: 10.1042/EBC20220016

Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P. & Griffioen, A. W. Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat. Rev. Clin. Oncol. 18, 527–540 (2021).

pubmed: 33833434 doi: 10.1038/s41571-021-00496-y

Davidson, S. et al. Fibroblasts as immune regulators in infection, inflammation and cancer. Nat. Rev. Immunol. 21, 704–717 (2021).

pubmed: 33911232 doi: 10.1038/s41577-021-00540-z

Ruan, R. et al. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. Mol. Cancer 22, 60 (2023).

pubmed: 36966334 pmcid: 10039534 doi: 10.1186/s12943-023-01761-7

Siefker-Radtke, A. O. et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann. Oncol. 35, 107–117 (2024).

pubmed: 37871702 doi: 10.1016/j.annonc.2023.10.003

Song, Y. et al. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. J. Immunother. Cancer 11, e006643 (2023).

pubmed: 37777251 pmcid: 10546120 doi: 10.1136/jitc-2022-006643

Okato, A. et al. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. J. Clin. Invest. 134, e169241 (2024).

pubmed: 38226620 pmcid: 10786699 doi: 10.1172/JCI169241

Rose, T. L. et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br. J. Cancer 125, 1251–1260 (2021).

pubmed: 34294892 pmcid: 8548561 doi: 10.1038/s41416-021-01488-6

Siefker-Radtke, A. O. et al. Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): final results from the phase 2 Norse study. J. Clin. Oncol. 41, 4504 (2023).

doi: 10.1200/JCO.2023.41.16_suppl.4504

Koshkin, V. S. et al. Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): preliminary safety results from a phase 2 study. J. Clin. Oncol. 40, 501 (2022).

doi: 10.1200/JCO.2022.40.6_suppl.501

Rosenberg, J. E. et al. Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study. J. Clin. Oncol. 39, 4521 (2021).

doi: 10.1200/JCO.2021.39.15_suppl.4521

Powles, T. B. et al. Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): first phase (Ph) II results from the NORSE study. Ann. Oncol. 32, S1303 (2021).

doi: 10.1016/j.annonc.2021.08.2103

Deshmukh, A. P. et al. Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing. Proc. Natl Acad. Sci. USA 118, e2102050118 (2021).

pubmed: 33941680 pmcid: 8126782 doi: 10.1073/pnas.2102050118

Oh, S. C. et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat. Commun. 9, 1777 (2018).

pubmed: 29725014 pmcid: 5934392 doi: 10.1038/s41467-018-04179-8

Dong, D. et al. FZD5 prevents epithelial-mesenchymal transition in gastric cancer. Cell Commun. Signal. 19, 21 (2021).

pubmed: 33618713 pmcid: 7898745 doi: 10.1186/s12964-021-00708-z

Ho, S. W. T. et al. Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. Gut 72, 226–241 (2023).

pubmed: 35817555 doi: 10.1136/gutjnl-2021-326483

Warzecha, C. C., Sato, T. K., Nabet, B., Hogenesch, J. B. & Carstens, R. P. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol. Cell 33, 591–601 (2009).

pubmed: 19285943 pmcid: 2702247 doi: 10.1016/j.molcel.2009.01.025

Zhao, Y. et al. Downregulated ESRP1/2 promotes lung metastasis of bladder carcinoma through altering FGFR2 splicing and macrophage polarization. Front. Immunol. 14, 1161273 (2023).

pubmed: 37090731 pmcid: 10113678 doi: 10.3389/fimmu.2023.1161273

Ashok, C. et al. E2F1 and epigenetic modifiers orchestrate breast cancer progression by regulating oxygen-dependent ESRP1 expression. Oncogenesis 10, 58 (2021).

pubmed: 34362878 pmcid: 8346533 doi: 10.1038/s41389-021-00347-6

Groulx, J. F., Boudjadi, S. & Beaulieu, J. F. MYC regulates α6 integrin subunit expression and splicing under its pro-proliferative ITGA6A form in colorectal cancer cells. Cancers 10, 42 (2018).

pubmed: 29401653 pmcid: 5836074 doi: 10.3390/cancers10020042

Gemmill, R. M. et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 300, 66–78 (2011).

pubmed: 20980099 doi: 10.1016/j.canlet.2010.09.007

Reinke, L. M., Xu, Y. & Cheng, C. Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition. J. Biol. Chem. 287, 36435–36442 (2012).

pubmed: 22961986 pmcid: 3476309 doi: 10.1074/jbc.M112.397125

Brown, W. S., Tan, L., Smith, A., Gray, N. S. & Wendt, M. K. Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer. Mol. Cancer Ther. 15, 2096–2106 (2016).

pubmed: 27371729 pmcid: 5010989 doi: 10.1158/1535-7163.MCT-16-0136

Sengal, A. T. et al. Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma. J. Pathol. Clin. Res. 8, 521–537 (2022).

pubmed: 35866380 pmcid: 9535101 doi: 10.1002/cjp2.286

Yashiro, M. et al. Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer. Sci. Rep. 11, 4698 (2021).

pubmed: 33633310 pmcid: 7907198 doi: 10.1038/s41598-021-84107-x

Minashi, K. et al. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer. Jpn J. Clin. Oncol. 51, 1523–1533 (2021).

pubmed: 34258618 pmcid: 8491535 doi: 10.1093/jjco/hyab104

Neumann, O. et al. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. Br. J. Cancer 127, 1540–1549 (2022).

pubmed: 35871236 pmcid: 9553883 doi: 10.1038/s41416-022-01908-1

Katoh, M. The integration of genomics testing and functional proteomics in the era of personalized medicine. Expert Rev. Proteom. 14, 1055–1058 (2017).

doi: 10.1080/14789450.2017.1392245

Halldorsson, B. V. et al. The sequences of 150,119 genomes in the UK Biobank. Nature 607, 732–740 (2022).

pubmed: 35859178 pmcid: 9329122 doi: 10.1038/s41586-022-04965-x

Martínez-Jiménez, F. et al. Pan-cancer whole-genome comparison of primary and metastatic solid tumours. Nature 618, 333–341 (2023).

pubmed: 37165194 pmcid: 10247378 doi: 10.1038/s41586-023-06054-z

Sternberg, C. N. et al. FORT-1: phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression. J. Clin. Oncol. 41, 629–639 (2022).

pubmed: 36240478 pmcid: 9870218 doi: 10.1200/JCO.21.02303

Velmahos, C. S., Badgeley, M. & Lo, Y. C. Using deep learning to identify bladder cancers with FGFR-activating mutations from histology images. Cancer Med. 10, 4805–4813 (2021).

pubmed: 34114376 pmcid: 8290253 doi: 10.1002/cam4.4044

Loeffler, C. M. L. et al. Artificial intelligence-based detection of FGFR3 mutational status directly from routine histology in bladder cancer: a possible preselection for molecular testing? Eur. Urol. Focus 8, 472–479 (2022).

pubmed: 33895087 doi: 10.1016/j.euf.2021.04.007

Mohammadi, M. et al. Structures of the tyrosine-kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276, 955–960 (1997).

pubmed: 9139660 doi: 10.1126/science.276.5314.955

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Masuko Katoh (M)

Yohann Loriot (Y)

Giovanni Brandi (G)

Simona Tavolari (S)

Zev A Wainberg (ZA)

Masaru Katoh (M)

Classifications MeSH